TPST | tickerfilter.com

Fundamental analysis

38%

Profitability 35%

Dept financing 33%

Liquidity 50%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

18.60%

1 Month

28.30%

3 Months

-17.41%

6 Months

-79.64%

1 Year

-70.82%

2 Year

-42.37%

Key data

Stock price

$2.04

P/E Ratio

0.00

DAY RANGE

$1.99 - $2.09

EPS

-$6.33

52 WEEK RANGE

$1.50 - $12.23

52 WEEK CHANGE

-$70.22

MARKET CAP

45.645 M

YIELD

N/A

SHARES OUTSTANDING

4.440 M

DIVIDEND

$0.00

EX-DIVIDEND DATE

04-09-2025

NEXT EARNINGS DATE

05-08-2025

BETA

3.46

PUBLIC FLOAT

AVERAGE 10 VOLUME

$181,815

AVERAGE 30 VOLUME

$293,281

Company detail

CEO: Stephen R. Brady
Region: US
Website: tempesttx.com
Employees: 20
IPO year: 2012

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Tempest Therapeutics Inc. engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors.

TPST - Tempest Therapeutics, Inc.